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Results  
 In PgR positive cases, there was no significant difference in the 
primary outcome of Ipsilateral breast recurrence between TARGIT 
and EBRT 2.3%(1.3-4.3) vs. 1.5%(0.75-3.0) p=0.51, and there were 
fewer deaths 2.7% (1.6-4.5) vs 4.9% (3.3-7.1) p=0.0487 
 
 In PgR negative cases there were more local recurrences after 
partial breast irradiation using TARGIT: 7.0%(3.5-13.6) vs.  
0.5%(0.1-3.7) p=0.017, but number of deaths was similar 8.1%(4.4-
14.7) vs. 6.3 (3.2-12.3). 
 
 Age, margin status, tumour grade, tumour size, vascular invasion, 
node positivity, ER and Her2 status were not found to be significant 
predictors. Even age younger than 50 or grade 3 cancers had similar 
outcome with TARGIT or EBRT.  
Conclusions 
 Progesterone receptor status could be useful in selecting cases for using PBI with targeted intraoperative radiotherapy (TARGIT) 
 When TARGIT is given concurrently with lumpectomy in PgR positive cases, local recurrence and breast cancer deaths are similar to 
EBRT and there are significantly fewer deaths from other causes (p=0.04), with a trend for improvement (3.1% higher) in overall survival.  
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How to select cases for TARGIT?: In this analysis we describe patient and tumour 
factors that may help select patients for TARGIT based on the results of an a priori 
statistical analysis plan.  
 
Background  
The TARGIT-A randomised trial compared a risk-adapted approach using targeted 
intraoperative radiotherapy (TARGIT) with whole breast external beam radiotherapy 
(EBRT) after lumpectomy for early breast cancer.  
 
December 2012 San Antonio Breast Cancer Symposium2 
Updated results: : 
the preferred option is to give TARGIT concurrently with 
lumpectomy (prepathology).  
 
 
Methods  
 Large international randomised trial:  33 centres in 10 countries  
 Randomisation to TARGIT vs. EBRT.  
 If unexpected high risk factors are found postoperatively, 
    after TARGIT, EBRT is added (in 15-20% of cases)  
 3451 patients  
 Age>=45, unifocal invasive ductal carcinoma, size <=3.5cm  
 Trial closed in June 2012 
 
Primary outcome  
Local recurrence in the conserved breast 
 
Seconday outcome 
Mortality – deaths from breast cancer and from other causes 
 
A priori hypothesis before unblinding for this analysis: 
Before unblinding for this analysis, we hypothesised that  
progesterone receptor (PgR) status, as an expression of a  
functionally active oestrogen receptor (ER), is a surrogate  
for radiation responsiveness and might be a predictive factor. 
 
We pre-specified a detailed analysis by PgR status.  
 
This was based on the finding in the recent EBCTCG overview that radiotherapy is more 
effective in hormone responsive tumours. Furthermore, the suggestion that a positive PgR 
status is necessary for a tumour to be called luminal A and the ELIOT study had found 
that IORT works better in luminal A tumours.  
 
We performed Kaplan Meier analysis for the primary and secondary end points as per 
PgR receptor status. 
 
We also analysed using the Cox proportional hazard model (age, margin status, tumour 
grade, ER, PgR, HER2,  vascular invasion and node positivity). 
Oxford overview Oct 2011 
10801 women in 17 trials 
When TARGIT was given concurrently in PgR positive 
cases (n=1625)  
 5-year risk of local recurrence in the conserved breast 
   TARGIT 4 events, 1.4%(0.46-3.9)  
      vs. 
    EBRT 5 events 1.2%(0.48-2.9)  
    HR 0.82(0.22-3.06) 
 
 5-year risk of overall mortality 
   TARGIT 18 deaths 3.3%(1.83-6.04)  
      vs.  
   EBRT 31 deaths 6.4%(4.3-9.6)  
    HR 0.60(0.34-1.08) 
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